Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969294 | 0.92 | HSP90AA1 (0.41) | MAPTHSP90AA1HSP90B1ALDH1A1MAPK10 | |
| SCHEMBL1964099 | 0.92 | HSP90B1 (0.41) | MAPTHSP90B1ALDH1A1PTGS2KDM4E | |
| SCHEMBL1966356 | 0.90 | AR (0.40) | MAPTALDH1A1MAPK10MEN1KMT2A | |
| SCHEMBL1965536 | 0.89 | KDM4E (0.45) | ALDH1A1MAPK10KDM4EMEN1KMT2A | |
| SCHEMBL1966964 | 0.85 | KDM4E (0.47) | HSP90AA1HSP90B1ALDH1A1KDM4EMEN1 | |
| SCHEMBL1964900 | 0.82 | HSP90B1 (0.46) | MAPTHSP90AA1HSP90B1ALDH1A1KDM4E | |
| SCHEMBL1971041 | 0.82 | EGLN1 (0.53) | MEN1KMT2A | |
| SCHEMBL1967836 | 0.81 | P2RX3 (0.39) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1967838 | 0.81 | P2RX3 (0.39) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1970228 | 0.79 | HIF1A (0.52) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2334682-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | Fibrogen, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | HIF1AN, HIF1A, EGLN3 | MAPT 4198/4885HSP90AA1 147/4885HSP90B1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.